LLY (Eli Lilly and Company) Trailing twelve months financial, business summary

Eli Lilly and Company

LLY

1169.60 (-1.71%) 20.04

Market cap

$1.04(T)

Earnings date

Oct-29-2026

Sector

Health Care

Industry

Pharmaceuticals

Eli Lilly and Company discovers develops manufactures and markets human pharmaceutical products in the United States Europe China Japan and internationally. The company offers cardiometabolic health products including Basaglar Humalog Humalog Mix 75/25 Humalog U-100 Humalog U-200 Humalog Mix 50/50 insulin lispro insulin lispro protamine insulin lispro mix 75/25 Humulin Humulin 70/30 Humulin N Humulin R Humulin U-500 for diabetes; Jardiance Mounjaro and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin’s lymphoma; and Verzenio for breast cancer. In addition the company offers immunology products which include Ebglyss; Olumiant; Omvoh; and Taltz. Further it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer’s disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech Inc. for lebrikizumab as well as license agreements with Almirall S.A. for Ebglyss; and Chugai Pharmaceutical Co. Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis Indiana.

EV: $1.06(T)

Total Equity: $33.88(B)

Debt/Equity: 1.62

Dividend/share: $6.5

Div. yield: 0.55%

P/E: 39.18

Forward P/E: 31.68

P/FCF: 57.33

P/S: 13.14

P/B: 30.78

EPS: $29.9

EPS (fwd): $36.9

FCF/share: $20.4

Revenue/share: $89.0

Book value/share: $38.0

ROIC: 32.9%

ROA: 19.3%

ROE: 96.8%

Margins: Gross | Op. | Net

83.4% | 45.1% | 33.5%

0.0%of Portfolio

My holdings

Day change

Total change

Overview Valuation Growth Financials & KPIs Competitors & Peer Comparison Ownership Tools All

PEvaluation

15%

$993

Based on a fair P/E of 21.7x and
forward EPS of $46.38

Valuation summary

Min—

Max—

Average—

Median—

Valuation comparison

Quality checklist score

6/8

Based on your selected metrics.

5Y Shares Out Change < 0% ROIC > 10% Current Ratio > 1 Net Margin > 10% Past Net Income CAGR > 0% Est. EPS Growth > 5%

Debt/Equity < 1 Quick Ratio > 1

TTM Financials

Income (TTM)

Revenue$79.67(B)

Gross profit$66.44(B)

EBITDA$41.71(B)

Net income$26.71(B)

Gross margin83.4%

Operating margin45.1%

Net margin33.5%

Shares outstanding891.36(M)

Balance sheet

Total assets$142.28(B)

Current assets$64.67(B)

Total liabilities$108.40(B)

Current liabilities$47.74(B)

Cash & Short-term inv.$8.95(B)

Long-term debt$47.86(B)

Total intangibles$26.96(B)

PP&E$29.29(B)

Cash flow (TTM)

FCF$18.19(B)

CapEx$-9.89(B)

Dividends paid$-5.79(B)

Stock issued$0

Stock repurchased$-6.17(B)

Stock-based comp.$649.00(M)

Debt issued$20.93(B)

Debt repaid$-5.71(B)

Per share data (TTM)

Price

$1170

Income

Revenue

$89.0•13.1x|7.6%

Gross profit

$74.5•15.7x|6.4%

Earnings (EPS)

$29.9•39.2x|2.6%

Cash flow

FCF

$20.4•57.3x|1.7%

Stock-based comp.

$0.73•1606.4x|0.1%

CapEx

$11.1•105.4x|0.9%

Dividend

$6.46•181.1x|0.6%

Balance sheet

Total assets

$160•7.3x|13.6%

Total liabilities

$122•9.6x|10.4%

Book value

$38.0•30.8x|3.2%

Cash & ST inv.

$10.0•116.5x|0.9%

Debt

$53.7•21.8x|4.6%

Forward earnings

EPS FY+1

$36.9•31.7x|3.2%

EPS FY+2

$47.5•24.6x|4.1%

EPS FY+3

$54.3•21.5x|4.6%

EPS FY+4

$60.6•19.3x|5.2%

EPS FY+5

$66.3•17.7x|5.7%

Forward FCF

FCF FY+1

$25.5•45.9x|2.2%

FCF FY+2

$34.1•34.3x|2.9%

FCF FY+3

$45.6•25.7x|3.9%

FCF FY+4

$53.0•22.1x|4.5%

FCF FY+5

$60.0•19.5x|5.1%

Summary

	Low	Avg	High	#
FY+1	35.5	36.9	40.8	27
FY+2	40.7	47.5	54.9	27
FY+3	46.5	54.3	62.8	21
FY+4	55.5	60.6	69.3	14
FY+5	60.6	66.3	74.5	14

About

Terms & privacy

Price charts & news courtesy of TradingView

Blog

Contact

First Stage Duration: 5 Years

Starting Free Cash Flow
First Stage Growth Rate
Low Mid High
Terminal Growth Rate
Low Mid High
Discount Rate

Forecast years: 5 Years

Terminal Growth Rate
Low Mid High
Discount Rate

Forecast years: 5 Years

Exit FCF Multiple
Low Mid High
Discount Rate

Annual Dividend
First Stage Length (Years): 0 Years

First Stage Growth Rate
Low Mid High
Final Growth Rate
Low Mid High
Discount Rate

Forecast years: 5 Years

Starting EPS
EPS Growth Rate
Low Mid High
Final P/E
Low Mid High
Discount Rate

Market cap

Earnings date

Category

Sector

Industry

TTM Financials

Income (TTM)

Balance sheet

Cash flow (TTM)

Per share data (TTM)

Summary

PEvaluation

Fair P/E

Margin of safety

EPS

Market Model

Economic moat: Very wide

EPS Estimates

Analyst Price Targets

Analyst Recommendations

2-stage DCF

Discounted Cash Flow

Free cash flow estimates:

Discounted Cash Flow (exit mult.)

Free cash flow estimates:

Dividend Discount Model

EPS Growth

Revenue Growth Valuation

Peter Lynch Fair Value

Graham Formula

Forecast Years: 10 Years

Base Revenue
Revenue Growth Rate
Low Mid High
Final Net Margin
Low Mid High
Final P/E Ratio
Low Mid High
Discount Rate

Earnings Per Share
EPS Growth (7-10 years)
Low Mid High
Government Bond Rate